ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices. Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems. This discontinuation follows several U.S. Food and Drug Administration (FDA) mandated CPAP recalls over the past several years adversely impacting an estimated 4 million patients.

ProSomnus precision intraoral devices have demonstrated excellent efficacy, adherence, and patient preference in numerous clinical studies, including a head-to-head cross over study comparing the effectiveness of treatment with ProSomnus devices versus CPAP devices. Further, ProSomnus is generally able to connect sleep physicians with local providers who are in-network with medical insurance, take Medicare and have demonstrated excellent results and high levels of patient satisfaction.

“ProSomnus along with our qualified providers are mobilized to facilitate access to high quality healthcare for the millions of patients suffering from untreated Obstructive Sleep Apnea,” commented Len Liptak, Chief Executive Officer of ProSomnus. “Scientific data from over a dozen studies, including hundreds of patients, establish ProSomnus devices as safe, effective, and patient preferred. We stand ready to help sleep physicians and their patients connect to qualified providers.”

“With this announcement by Philips Respironics, I believe that the public in need of treatment for OSA is becoming more disenfranchised,” stated Dr. Kent Smith, D-ABDSM, ASBA. “It is past the time for the PAP community of healthcare providers to partner with qualified Dental Sleep Medicine (DSM) providers to facilitate a less restrictive avenue for treatment. We will hear of stricter allocation of PAP units soon, and I believe it would benefit the patients needing help to be provided with other options. I hope that PAPs would be reserved for the most severe population while those with less severe disease levels would be offered Oral Appliance Therapy, which has been found to be very effective in this subset of patients.”